Quaterly Results | Bafna Pharmaceuticals Ltd. | R Wadiwala Securities Pvt Ltd

BAFNA PHARMACEUTICALS LTD.

NSE : BAFNAPHBSE : 532989ISIN CODE : INE878I01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE149.002.65 (+1.81 %)
PREV CLOSE (Rs.) 146.35
OPEN PRICE (Rs.) 145.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 211
TODAY'S LOW / HIGH (Rs.)145.35 149.00
52 WK LOW / HIGH (Rs.)67.8 204.95
NSE143.39-2.2 (-1.51 %)
PREV CLOSE( Rs. ) 145.59
OPEN PRICE (Rs.) 142.71
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13969
TODAY'S LOW / HIGH(Rs.) 142.68 144.95
52 WK LOW / HIGH (Rs.)69 202.06

Quarterly Results

Quarters
Select year
Particulars
Mar 2020
Dec 2019
Sep 2019
Jun 2019
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
131.33
109.25
115.65
68.49
Total Expenditure
88.88
107.04
119.41
97.16
PBIDT (Excl OI)
42.45
2.21
-3.76
-28.67
Other Income
-6.71
0.33
5.91
3.02
Operating Profit
35.74
2.54
2.15
-25.65
Interest
0.25
-1.01
0.45
1.27
Exceptional Items
-8.41
-217.17
NA
NA
PBDT
27.08
-213.62
1.70
-26.92
Depreciation
5.25
10.01
7.23
10.18
Profit Before Tax
21.83
-223.63
-5.53
-37.10
Tax
15.78
-0.35
0.40
-15.82
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
6.05
-223.28
-5.93
-21.28
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
6.05
-223.28
-5.93
-21.28
Minority Interest
-2.87
NA
NA
NA
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
3.18
-223.29
-5.90
-21.28
Equity Capital
23.66
236.56
236.56
236.56
Face Value (IN RS)
10.00
10.00
10.00
10.00
Reserves
NA
NA
NA
NA
Calculated EPS
2.55
-9.44
-0.25
-0.90
Calculated EPS (Annualised)
10.21
-37.76
-1.00
-3.60
No of Public Share Holdings
1741143.00
17420470.00
17420470.00
17420470.00
% of Public Share Holdings
73.60
73.64
73.64
73.64
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
32.32
2.02
-3.25
-41.86
PBIDTM%
27.21
2.32
1.86
-37.45
PBDTM%
20.62
-195.53
1.47
-39.31
PBTM%
16.62
-204.70
-4.78
-54.17
PATM%
4.61
-204.38
-5.13
-31.07
 
Notes
Notes
Notes
Notes